store at low temperature | store at -20°C
Elotuzumab(HuLuc 63) (anti-SLAMF7) 是一种靶向 SLAMF7 受体的单克隆抗体。Elotuzumab (anti-SLAMF7) 是一种直接激活NK细胞并诱导抗体依赖性细胞毒性的化合物,可联合来那度胺和地塞米松 (Ld) 用于治疗多发性骨髓瘤。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,880 | 现货 | ||
5 mg | ¥ 5,720 | 现货 | ||
10 mg | ¥ 7,730 | 现货 | ||
25 mg | ¥ 11,300 | 现货 | ||
50 mg | ¥ 15,500 | 现货 |
产品描述 | Elotuzumab(HuLuc 63) is a monoclonal antibody that targets the SLAMF7 receptor.Elotuzumab is a compound that directly activates NK cells and induces antibody-dependent cytotoxicity, and can be used in combination with lenalidomide and dexamethasone (Ld) to treat multiple myeloma. |
体内活性 | Elotuzumab (anti-SLAMF7) was given at 10 mg/kg weekly for the first two treatment cycles (28 days/cycle), followed by 10 mg/kg every other week for all subsequent cycles. Four different Elotuzumab (anti-SLAMF7) combination therapies were administered: 1) Elotuzumab (anti-SLAMF7) and dexamethasone 2) Elotuzumab (anti-SLAMF7), lenalidomide and dexamethasone 3) Elotuzumab (anti-SLAMF7), pomalidomide and dexamethasone and 4) Elotuzumab (anti-SLAMF7), carfilzomib, pomalidomide, and dexamethasone. We found that regardless of Elotuzumab (anti-SLAMF7) combination therapy, all patients treated showed decreased phosphorus levels after initiating Elotuzumab (anti-SLAMF7) treatment with reductions ranging from 12.5% to 44.1% below baseline. Six participants (67%) demonstrated average serum phosphorus at or below 2.5 mg/dL after starting Elotuzumab (anti-SLAMF7) therapy.[2] |
别名 | Elotuzumab (anti-SLAMF7), BMS 901608, PDL 063, HuLuc 63 |
分子量 | N/A |
CAS No. | 915296-00-3 |
store at low temperature | store at -20°C
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Elotuzumab 915296-00-3 Others PDL-063 PDL063 Elotuzumab (anti-SLAMF7) BMS-901608 BMS 901608 PDL 063 anti-SLAMF7 BMS901608 HuLuc 63 Inhibitor inhibitor inhibit